Spoken Alpha
INO
INOVIO PHARMACEUTICALS, INC.
Overview
Inovio Pharmaceuticals designs DNA medicines and electroporation delivery devices to treat HPV-related diseases, cancers, and infectious diseases. The company's lead candidate, INO-3107, is a DNA immunotherapy for recurrent respiratory papillomatosis (RRP) that teaches the body's cells to produce proteins targeting HPV-infected cells.
INOVIO PHARMACEUTICALS, INC is a Healthcare company operating in Biotechnology with a $93.0M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 11, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-1313 Q&A exchanges
- Q4 FY2025Earnings2026-03-128 Q&A exchanges
- Q3 FY2025Earnings2025-11-106 Q&A exchanges
- Q2 FY2025Earnings2025-08-1317 Q&A exchanges
- Q1 FY2025Earnings2025-05-1318 Q&A exchanges
- Q4 FY2024Earnings2025-03-1822 Q&A exchanges
- Q3 FY2024Earnings2024-11-1421 Q&A exchanges
- Q2 FY2024Earnings2024-08-099 Q&A exchanges
- Q1 FY2024Earnings2024-05-1315 Q&A exchanges
- Q4 FY2023Earnings2024-03-0615 Q&A exchanges
- Q3 FY2023Earnings2023-11-098 Q&A exchanges
- Q2 FY2023Earnings2023-08-0910 Q&A exchanges
- Q1 FY2023Earnings2023-05-1011 Q&A exchanges
- Q4 FY2022Earnings2023-03-0111 Q&A exchanges
- Q3 FY2022Earnings2022-11-089 Q&A exchanges
- Q2 FY2022Earnings2022-08-098 Q&A exchanges
- Q1 FY2022Earnings2022-05-1010 Q&A exchanges
- Q4 FY2021Earnings2022-03-0116 Q&A exchanges
- Q3 FY2021Earnings2021-11-0928 Q&A exchanges
- Q2 FY2021Earnings2021-08-0923 Q&A exchanges
- Q1 FY2021Earnings2021-05-1012 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-11EPS— vs $-0.27—Rev— vs ——EODHD
- Q1 FY20262026-05-13EPS$-0.31 vs $-0.33+4.7%Rev$0 vs ——EODHD
- Q4 FY20252026-03-12EPS$-0.28 vs $-0.34+19.6%Rev$-65.3K vs ——EODHD
- Q3 FY20252025-11-09EPS$-0.87 vs $-0.99+12.1%Rev$0 vs ——EODHD
- Q2 FY20252025-08-11EPS$-0.61 vs $-1.07+43.0%Rev$0 vs ——EODHD
- Q1 FY20252025-05-11EPS$-0.51 vs $-0.74+31.1%Rev$65.3K vs ——EODHD
- Q4 FY20242025-03-03EPS$-0.60 vs $-0.83+27.9%Rev$117.0K vs ——EODHD
- Q3 FY20242024-11-06EPS$-0.89 vs $-1.15+22.6%Rev$0 vs ——EODHD
- Q2 FY20242024-08-07EPS$-1.19 vs $-1.10-8.2%Rev$100.8K vs ——EODHD
- Q1 FY20242024-05-12EPS$-1.31 vs $-1.00-31.0%Rev$0 vs ——EODHD
- Q4 FY20232024-03-05EPS$-1.12 vs $-1.27+11.8%Rev$102.7K vs ——EODHD
- Q3 FY20232023-11-08EPS$-0.13 vs $-0.130.0%Rev$388.4K vs ——EODHD
- Q2 FY20232023-08-08EPS$-0.13 vs $-0.14+7.1%Rev$226.0K vs ——EODHD
- Q1 FY20232023-05-09EPS$-0.16 vs $-0.14-14.3%Rev$114.9K vs ——EODHD
- Q4 FY20222023-02-28EPS$-0.21 vs $-0.17-23.5%Rev$124.7K vs ——EODHD
- Q3 FY20222022-11-07EPS$-0.15 vs $-0.30+50.0%Rev$9.2M vs ——EODHD
- Q2 FY20222022-08-08EPS$-0.46 vs $-0.31-48.4%Rev$784.4K vs ——EODHD
- Q1 FY20222022-05-09EPS$-0.36 vs $-0.34-5.9%Rev$199.1K vs ——EODHD
- Q4 FY20212022-02-28EPS$-0.50 vs $-0.32-56.3%Rev$839.1K vs ——EODHD
- Q3 FY20212021-11-08EPS$-0.29 vs $-0.33+12.1%Rev$291.7K vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-11 | — | $-0.27 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-13 | $-0.31 | $-0.33 | +4.7% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-12 | $-0.28 | $-0.34 | +19.6% | $-65.3K | — | — | EODHD |
| Q3 FY2025 | 2025-11-09 | $-0.87 | $-0.99 | +12.1% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-0.61 | $-1.07 | +43.0% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-11 | $-0.51 | $-0.74 | +31.1% | $65.3K | — | — | EODHD |
| Q4 FY2024 | 2025-03-03 | $-0.60 | $-0.83 | +27.9% | $117.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $-0.89 | $-1.15 | +22.6% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $-1.19 | $-1.10 | -8.2% | $100.8K | — | — | EODHD |
| Q1 FY2024 | 2024-05-12 | $-1.31 | $-1.00 | -31.0% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-05 | $-1.12 | $-1.27 | +11.8% | $102.7K | — | — | EODHD |
| Q3 FY2023 | 2023-11-08 | $-0.13 | $-0.13 | 0.0% | $388.4K | — | — | EODHD |
| Q2 FY2023 | 2023-08-08 | $-0.13 | $-0.14 | +7.1% | $226.0K | — | — | EODHD |
| Q1 FY2023 | 2023-05-09 | $-0.16 | $-0.14 | -14.3% | $114.9K | — | — | EODHD |
| Q4 FY2022 | 2023-02-28 | $-0.21 | $-0.17 | -23.5% | $124.7K | — | — | EODHD |
| Q3 FY2022 | 2022-11-07 | $-0.15 | $-0.30 | +50.0% | $9.2M | — | — | EODHD |
| Q2 FY2022 | 2022-08-08 | $-0.46 | $-0.31 | -48.4% | $784.4K | — | — | EODHD |
| Q1 FY2022 | 2022-05-09 | $-0.36 | $-0.34 | -5.9% | $199.1K | — | — | EODHD |
| Q4 FY2021 | 2022-02-28 | $-0.50 | $-0.32 | -56.3% | $839.1K | — | — | EODHD |
| Q3 FY2021 | 2021-11-08 | $-0.29 | $-0.33 | +12.1% | $291.7K | — | — | EODHD |
Source: EODHD. INO reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks INO's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 80% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $4.75 | $4.31 | +10.3% | -3.4% | -3.6% |
| Q4 FY2026 | $4.71 | $4.24 | +11.2% | -1.5% | -4.5% |
| Q3 FY2026 | $5.14 | $4.28 | +20.2% | -5.1% | -5.1% |
| Q2 FY2026 | $4.79 | $4.31 | +11.2% | -8.0% | -5.2% |
| Q1 FY2025 | $4.88 | $4.13 | +18.1% | -6.4% | -3.9% |
| Q4 FY2025 | $4.87 | $4.26 | +14.3% | +1.6% | -0.7% |
| Q3 FY2025 | $4.60 | $4.20 | +9.5% | -0.1% | +2.6% |
| Q2 FY2025 | $4.65 | $4.22 | +10.2% | -3.2% | -3.5% |
| Q1 FY2024 | $4.77 | $4.33 | +10.1% | +1.0% | +0.5% |
| Q4 FY2024 | $5.29 | $4.47 | +18.4% | -3.3% | -4.8% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Jacqueline Elizabeth SheaCEO1 yr 4 mono recorded callsCurrentSample
CEO since 2025 • 2/4 beats (50%) • last guidance cut Q2 FY2026
- Peter KiesCFO1 yr 4 mo21 callsCurrentSample
CFO since 2025 • 3/4 beats (75%) • last guidance cut Q1 FY2026
- Laurent HumeauChief Scientific Officer1 yr 4 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 2/4 beats (50%) • last guidance raise Q1 FY2026
- Michael John SumnerChief Medical Officer2 yrno recorded callsCurrentSample
OTHER_C_SUITE since 2024 • 6/8 beats (75%) • last call held guidance Q2 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for INO.
$ curl https://api.spokenalpha.com/v1/companies/INOFAQ
Frequently asked about INO
Where can I find INOVIO PHARMACEUTICALS, INC.'s (INO) earnings call transcripts?
Spoken Alpha indexes INO's earnings call transcripts at https://spokenalpha.com/companies/INO. Each call links to attributed speakers and parsed analyst Q&A. INOVIO PHARMACEUTICALS, INC.'s own investor relations page is at https://ir.inovio.com/overview/default.aspx.
When was INOVIO PHARMACEUTICALS, INC.'s most recent earnings call?
INOVIO PHARMACEUTICALS, INC. (INO) held its most recent earnings call on 2026-05-13, covering fiscal Q1 2026.
What sector is INO in?
INOVIO PHARMACEUTICALS, INC. (INO) operates in the Healthcare sector (Biotechnology industry).